Natural History of Relapsed MM After Initial Relapse

Conference Correspondent  - TON - ASH 2015 - Multiple Myeloma, Conference Correspondent

The range of treatment options for patients with multiple myeloma (MM) has grown substantially in recent years, and many patients now receive combinations containing immunomodulatory drugs (IMiDs) and proteasome inhibitors as initial treatment. However, patients with MM invariably relapse after their initial treatment and require successive therapies to maintain disease control. Increased access to new therapies for treatment of relapsed disease has led to improved survival of patients with MM. However, the natural history of relapsed myeloma earlier in the course of relapsed disease has not been studied in detail. 

To more closely examine the natural history of relapsed MM earlier in the course of relapsed disease, researchers designed a global, multicenter, retrospective study to examine the current treatment approaches for initial relapses in MM and patient outcomes following application of successive treatment regimens. Patients with MM who experienced a first relapse between January 1, 2007, and December 31, 2011, were identified for inclusion in the study. Clinical and laboratory data were culled from medical records from the time of diagnosis through patients’ third relapse.

The study population included 315 patients, 59% of which were male. Median age at diagnosis was 59 years. An IMiD (thalidomide or lenalidomide), bortezomib, or alkylating agent (melphalan or cyclophosphamide) was part of the initial therapy in 63%, 36%, and 51% of patients, respectively. In addition, 93 (30%) patients had stem-cell transplantation as part of initial treatment. An IMiD (thalidomide, lenalidomide, or pomalidomide), proteasome inhibitor (bortezomib or carfilzomib), or alkylating agent (melphalan or cyclophosphamide) was part of the therapy for first relapse in 50%, 59%, and 33% of patients, respectively. The following table shows responses, as measured by the overall survival, progression-free survival, and time to next treatment for each line of therapy subsequent to the first date of treatment with an antimyeloma regimen for first disease relapse.

Treatment Outcomes After Initial Relapse (median months)
End Point Overall survival Progression-free survival Time to next treatment
2nd Line of Therapy (n = 307) 36.1 18.4 12.6
3rd Line of Therapy (n = 163) 13.4 8.3 6.4
4th Line of Therapy (n = 84) 15 9.8 6.6

This study clearly demonstrates the progressively shorter duration of disease control with each successive treatment regimen, reflecting concerns about cumulative drug resistance over time. Newer therapies have had a positive impact on overall survival from time of first relapse, but these results underscore the need for additional treatment options with novel mechanisms of action.

Related Items
Palliative Care Use Dismal Among Patients with Hematologic Malignancies
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, ASH, Palliative Care, Hematologic Cancers
Oral Multiple Myeloma Medication Linked to Decreased Productivity Loss
Chase Doyle
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, ASH, Multiple Myeloma
Ivosidenib, New IDH1 Inhibitor, Elicits Complete Response in Relapsed Acute Myeloid Leukemia
Wayne Kuznar
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, Drug Updates & News, ASH
“Superhero” Navigators Convene at the 8th Annual Navigation & Survivorship Conference
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, AONN+ News
Silent Patients Find Their Voices Through an Advocate’s Journey
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Patient Advocacy, Conference Correspondent, ESMO
Measuring Financial Well-Being in Cancer Survivorship
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, Survivorship
Combining Immunotherapy and Radiotherapy Shows Good Synergy
Chase Doyle
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Immunotherapy, Conference Correspondent
Quizartinib Combinations Show High Activity in Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation
Wayne Kuznar
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, Drug Updates & News
Humanizing Cancer Care: The Patient Perspective
Gail Thompson
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, ACCC
Emerging Safety Data with Checkpoint Inhibitors
Phoebe Starr
TON - November 2017, Vol 10, No 6 published on November 27, 2017 in Conference Correspondent
Last modified: December 5, 2017